why do you continue to apply "turn-a -around " status to bmsn, when it is a start up biotech company ? as for cash on hand, you'll see on the latest balance sheet, bmsn ,like most small biotech companies, has very little on hand. hopefully big pharmas will help with that problem. currently their biggest hurdle is to get fda approval. along with their amazing pipeline of potential drugs, this company has a very bright future.